Clark Estates Inc. NY Sells 22,507 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Clark Estates Inc. NY lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 10.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 185,743 shares of the biopharmaceutical company's stock after selling 22,507 shares during the period. Catalyst Pharmaceuticals comprises approximately 0.7% of Clark Estates Inc. NY's holdings, making the stock its 20th largest holding. Clark Estates Inc. NY owned about 0.16% of Catalyst Pharmaceuticals worth $3,876,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Pacer Advisors Inc. boosted its position in shares of Catalyst Pharmaceuticals by 5.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company's stock worth $61,681,000 after purchasing an additional 151,495 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Catalyst Pharmaceuticals by 6.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company's stock worth $26,023,000 after purchasing an additional 79,182 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Catalyst Pharmaceuticals by 1.3% in the 4th quarter. Bank of New York Mellon Corp now owns 723,545 shares of the biopharmaceutical company's stock worth $15,100,000 after purchasing an additional 9,194 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Catalyst Pharmaceuticals by 4.3% in the 4th quarter. Principal Financial Group Inc. now owns 600,488 shares of the biopharmaceutical company's stock worth $12,532,000 after purchasing an additional 24,535 shares in the last quarter. Finally, abrdn plc bought a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $10,115,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Remove Ads

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Steve Miller sold 50,000 shares of the firm's stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 157,879 shares of company stock worth $3,535,595 in the last ninety days. Insiders own 11.00% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently commented on CPRX. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Robert W. Baird boosted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. Stephens reissued an "overweight" rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Bank of America reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Finally, Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $32.50.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock traded up $0.29 on Friday, reaching $21.96. The stock had a trading volume of 1,021,369 shares, compared to its average volume of 1,261,681. The stock has a market cap of $2.67 billion, a P/E ratio of 18.61, a price-to-earnings-growth ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.47 and a 1 year high of $24.64. The company has a 50 day simple moving average of $22.28 and a 200 day simple moving average of $21.51.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.